Miller Fisher Syndrome Induced by Chemotherapy in Known Case of Acute Lymphocytic Leukaemia: A Case Report

Introduction: Guillain-Barre Syndrome (GBS) is an acute-onset autoimmune-mediated neuropathy. can be divided into three subtypes: acute inflammatory demyelinating poly-radiculo-neuropathy (AIDP), motor axonal neuropathy (AMAN), and sensory (AMSAN). About 20% of patients with GBS develop respiratory failure require mechanical ventilation. We are presenting a variant (Miller Fisher Syndrome, or MFS), which has been confirmed by nerve conduction studies along the triad ophthalmoplegia, ataxia, areflexia. The objective this study to present rare case chemotherapy-induced GBS. Important clinic findings: A 25-year-old gentleman lymphocytic leukemia on active chemotherapy treatment presented lower limb weakness. This weakness started after his fifth session. After sixth chemotherapy, he developed complete paralysis left limb. Later, right paralysis. He was also complaining eye dryness incomplete closure both eyes. While inpatient, upper-limb His consisted MESNA, cyclophosphamide, doxorubicin, vincristine, cyorabine, methotrexate. had ptosis ophthalmoplegia in abducent oculomotor regions. bilateral facial palsy. hypotonic power grade 3 upper limbs 0 sensation intact but lost limbs. planter reflexes were mute. Diagnoses Management: Intravenous immunoglobulins given for 5 days. showed severe sensorimotor polyradoculoneuropathy secondary loss. areflexia consistent MFS. patient improved over course hospital stay did not reach full recovery. Conclusion: Although uncommon, it must taken account when making differential diagnosis any progressive Drug history important all cases.